Doxorubicin cardiac toxicity manifesting seven years after treatment. Case report and review.
This report describes a patient treated for lymphoma who had development of doxorubicin (Adriamycin) cardiotoxicity proved by endomyocardial biopsy seven years after treatment. Doxorubicin cardiotoxicity is reviewed with emphasis on the implications of the long latency period for anthracycline cardiotoxicity in patients treated with this widely used antineoplastic agent.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001706:Biopsy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects* / Q000627:therapeutic use; D004699:Endocardium / Q000473:pathology; D005260:Female; D006333:Heart Failure / Q000139:chemically induced / Q000473:pathology; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008875:Middle Aged; D009206:Myocardium / Q000473:pathology; D011241:Prednisone / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone